Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial

Psoriasis

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Lancet.

Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H

doi: 10.1016/S0140-6736(18)31713-6.

Psoriasis

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

JAMA Dermatol.

Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG

doi: 10.1001/jamadermatol.2020.0723.

COMMENTED

Psoriasis

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Lancet.

Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C

doi: 10.1016/S0140-6736(19)30952-3.

Psoriasis

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomised, controlled trial

J Eur Acad Dermatol Venereol

Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, Papanastasiou P, Keefe D, Patekar M, Charef P, Zhang L, Cafoncelli S, Papavassilis C

doi: 10.1111/jdv.17002

Psoriasis

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial

Br J Dermatol.

Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K, IXORA-R Study Group

doi: 10.1111/bjd.19509.

Psoriasis

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Lancet

Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A

doi: 10.1016/S0140-6736(21)00126-4

Psoriasis

Sustained Long-Term Efficacy and Safety of Adalimumab in Pediatric Patients with Severe Chronic Plaque Psoriasis from a Randomised, Double-Blind, Phase 3 Study

Br J Dermatol.

Thaçi D, Papp K, Marcoux D, Weibel L, Pinter A, Ghislain PD, Landells I, Hoeger PH, Unnebrink K, Seyger MMB, Williams DA, Rubant S, Philipp S

doi: 10.1111/bjd.18029.

Psoriasis

A phase 4, randomised, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)

J Eur Acad Dermatol Venereol.

Pinter A, Hoffmann M, Reich K, Augustin M, Kaplan K, Gudjónsdóttir SD, Delvin T, Mrowietz U, CHANGE investigator group.

doi: 10.1111/jdv.16932.

Psoriasis

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial

Br J Dermatol.

Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, Jiang J, Li S, Puig L

doi: 10.1111/bjd.15750.

Related content

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomised, controlled trial

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Sustained Long-Term Efficacy and Safety of Adalimumab in Pediatric Patients with Severe Chronic Plaque Psoriasis from a Randomised, Double-Blind, Phase 3 Study

A phase 4, randomised, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial